# Windgap Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/windgap-medical

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.windgapmedical.com
- Total disclosed funding: $24M
- Latest round: Series B (Jan 25, 2022)
- Investors on record: 7

## About

Windgap Medical Inc. is focused on developing and commercializing innovative drug delivery devices, including advanced autoinjectors and liquid-vial delivery systems, aimed at enhancing the administration of complex injectables.Founded in 2011 and headquartered in Watertown, US, Windgap Medical Inc. specializes in innovative drug delivery solutions. The company was co-founded by Brent Buchine and Chris Stepanian, and currently led by CEO Aaron Mann and Chris Stepanian. The firm has successfully completed 11 deals, with its most recent funding round being a Series B in January 2022, raising USD 22.15 million led by Taiwania Capital, with participation from Cobro Ventures and returning investors. The total amount raised by the company is USD 22.15 million, and it has a current valuation of USD 130.33 million.Windgap Medical, Inc. specializes in innovative drug delivery products, including the ANDIPen®? and proprietary liquid-vial delivery systems. These devices are designed to simplify the administration of complex injectables and enhance patient experiences by minimizing reconstitution time and allowing multi-therapy delivery through a single needle. Their clientele includes leading biopharmaceutical companies across North America, Europe, and Asia, addressing the needs for sophisticated drug delivery solutions.Windgap Medical generates revenue through partnerships with major biopharmaceutical firms, focusing on B2B transactions. The company collaborates with pharmaceutical manufacturers to create customized autoinjector products. Its revenue model includes project-based contracts that provide services and products like the ANDIPen®?, alongside regulatory consultation. Pricing is based on individual contracts, and the firm’s extensive patent portfolio strengthens its market position, ensuring sustained revenue growth through established industry relationships.Windgap Medical plans to utilize the USD 22.15 million raised in its Series B funding, led by Taiwania Capital, to advance its ongoing commercialization process for epinephrine and expand its product pipeline utilizing autoinjector technology. The company aims to enhance its offerings and penetrate new markets by introducing upcoming products in the drug delivery sector. Specific targeted regions for expansion include North America and Europe, aligning with the growing demand for sophisticated drug delivery solutions.

## Funding rounds

- Series B, Jan 25, 2022, $22M — Shepherd Kaplan Krochuk, Cobro Ventures, Molex Ventures, Taiwania Capital
- Seed, Apr 9, 2014, $1.5M — Cherrystone Angel Group, Maine Angels, Beta Fund

## Investors

- Cherrystone Angel Group (https://capitalatlas.ai/funds/cherrystone-angel-group) — Seed
- Maine Angels — Seed
- Beta Fund (https://capitalatlas.ai/funds/beta-fund) — Seed
- Shepherd Kaplan Krochuk (https://capitalatlas.ai/funds/shepherd-kaplan-krochuk) — Series B
- Cobro Ventures (https://capitalatlas.ai/funds/cobro-ventures) — Series B
- Molex Ventures (https://capitalatlas.ai/funds/molex-ventures) — Series B
- Taiwania Capital (https://capitalatlas.ai/funds/taiwania-capital) — Series B